Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer
Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer
复制标题
DOI：
10.3892/ol.2015.3691
复制
发表时间：
2015-11-01
期刊：
影响因子：
2.9
通讯作者：
Wild, Peter J.
中科院分区：
文献类型：
--
作者：
Poyet, Cedric;Hermanns, Thomas;Wild, Peter J.
除了常规的临床病理参数外，还需要分子标记来预测膀胱尿路上皮癌（BC）患者的病程。关于成纤维细胞生长因子受体 3 (FGFR3) 免疫反应性及其对 BC 可能具有的临床意义知之甚少。本研究旨在探讨 FGFR3 在原发性膀胱尿路上皮肿瘤中的免疫反应性，包括临床病理特征和 FGFR3 突变状态。使用组织微阵列对 255 名未经选择的原发性 BC 患者的 FGFR3 表达进行免疫组织化学分析。使用 SNaPshot 分析检测 FGFR3 突变。在 113/207 个可分析病例 (54.6%) 中发现了阳性 FGFR3 免疫反应性，并且与 FGFR3 突变显着相关 (P
In addition to conventional clinicopathological parameters, molecular markers are also required in order to predict the course of disease in patients with urothelial bladder cancer(BC). Little is known about fibroblast growth factor receptor 3 (FGFR3) immunoreactivity and the clinical significance it may possess with regard to BC. The present study aimed to investigate the immunoreactivity of FGFR3 in primary urothelial bladder tumours, with regard to clinicopathological features and FGFR3 mutation status. Tissue microarrays were used to immunohistochemically analyse FGFR3 expression in 255 primary, unselected patients with BC. FGFR3 mutations were detected using SNaPshot analysis. Positive FGFR3 immunoreactivity was identified in 113/207 analysable cases (54.6%), and was significantly associated with FGFR3 mutation (P